Passage Bio stock reacts to reverse split as investors watch next steps

Passage Bio stock has undergone a 1-for-20 reverse split, leaving investors focusing on the companys next strategic steps and the reduced share count while monitoring the small-cap biotech valuation.

Passage Bio stock (ISIN US70267E1055) has drawn fresh attention as of September 2, 2026 after a 1-for-20 reverse stock split reduced the number of outstanding shares and reset the trading price for the gene therapy specialist.

Reverse split reshapes Passage Bio capital structure

According to a corporate actions overview dated early September 2026, Passage Bio, Inc. carried out a 1-for-20 reverse split, meaning investors now hold 1 PASG share for every 20 shares previously held, with any fractional entitlements rounded up to the nearest whole share.

This move is typical for small biotechnology companies whose share price had fallen to levels that could jeopardize continued listing on a major exchange, and it effectively multiplies the share price by 20 while cutting the share count by the same factor without changing the overall market capitalization.

Valuation signal from recent market data

Recent market data compiled as of September 1, 2026 indicate that Passage Bio, Inc. is categorized within the biotechnology industry and has a market capitalization figure of about 14.255 million USD, highlighting how small the company remains within the wider health care universe.

That valuation figure suggests that even after the reverse stock split, Passage Bio trades as a micro cap, and investors will be sensitive to any change in clinical or strategic news flow because even modest capital inflows or outflows can shift a 14.255 million USD market value noticeably.

Gene therapy pipeline remains in investor focus

Passage Bio, Inc. is a clinical stage biotechnology company developing gene therapies for central nervous system disorders, and for investors the commercial prospects of its pipeline programs remain the decisive driver for future valuation beyond the mechanical effect of the reverse split.

Stock reflects micro-cap biotech risks

Given a market capitalization of about 14.255 million USD as of September 1, 2026 and the recent 1-for-20 reverse split, Passage Bio stock embodies the high risk high reward profile typical of early stage gene therapy developers, with significant sensitivity to clinical milestones and financing decisions.

Passage Bio at a glance

• Company: Passage Bio, Inc.
• ISIN: US70267E1055
• Ticker: PASG
• Trading venue: NASDAQ
• Market capitalization: 14.255 million USD (as of September 1, 2026)
• Sector / Industry: Health care / Biotechnology
• Index membership: None